Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GiCIIS: Ginkgo Biloba Extract in Cognitive Impairment After Ischemic Stroke
NCT07220538Phase 4Active, not recruiting
- Sponsor
- Dr. Willmar Schwabe
- Start
- Nov 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in cognitive impairment comparing Extract of Ginkgo Biloba Leaves Tablets + SoC with Standard of Care (2 arms). Primary endpoints: Montreal Cognitive Assessment at 52 weeks, Trail Making Test Parts A and B at 52 weeks and 6 more. Started Nov 2025; status: active, not recruiting.
02
Drugs
ginkgo biloba extract
03
Conditions
cognitive impairment
Beyond the preview
Go deeper on NCT07220538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07220538.